Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
---|---|
Information provided by: | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
ClinicalTrials.gov Identifier: | NCT00000435 |
A small protein called dnaJ peptide may help people with rheumatoid arthritis (RA) by preventing their immune system cells from attacking their own tissues. The purpose of this study is to determine if small amounts of dnaJ peptide can "re-educate" immune cells in people with RA so that the cells stop attacking joint tissues.
Condition | Intervention | Phase |
---|---|---|
Rheumatoid Arthritis |
Drug: dnaJ peptide Drug: None-placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis (RA) |
Enrollment: | 160 |
Study Start Date: | September 1999 |
Estimated Study Completion Date: | September 2004 |
Arms | Assigned Interventions |
---|---|
A: Placebo Comparator
Subjects randomized to arm A received 25mg/day po of placebo
|
Drug: None-placebo
placebo was taken in pill form at 25mg/day for 6 months
|
B: Active Comparator
Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
|
Drug: dnaJ peptide
dnaJP1 was taken in pill form at 25mg/day for 6 months
|
Immune modulation is a promising new approach for the treatment of RA. Studies have shown that immune cells in the joints of people in the early stages of RA react strongly against dnaJ peptides from bacteria. These immune cells may also cross-react with human dnaJ peptides in the joints to cause inflammation. dnaJ may help RA by "re-educating" the immune system and dampening the abnormal inflammatory immune response in RA.
This study will last 7 months. Participants will be randomly assigned to receive either dnaJ or placebo by mouth. At screening, participants will have medical history, physical, and medication assessment. At screening, at 6 study visits every month after the start of treatment, and at 1 month follow-up, participants will have a joint exam, blood and urine collection, and will fill out a questionnaire about their condition.
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
University of Arizona Health Sciences Center | |
Tucson, Arizona, United States, 85724-5093 | |
United States, California | |
Stanford University | |
Palo Alto, California, United States, 94305 | |
University of California, Irvine Medical Center | |
Orange, California, United States, 92868 | |
United States, Colorado | |
Denver Arthritis Center | |
Denver, Colorado, United States, 80230 | |
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21224 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, Pennsylvania | |
Guthrie Clinic | |
Sayre, Pennsylvania, United States, 18840 | |
United States, Washington | |
Virginia Mason Research Center | |
Seattle, Washington, United States, 98104 |
Principal Investigator: | Salvatore Albani, MD | University of California, San Diego |
Study ID Numbers: | N01 AR92241, NIAMS-042 |
Study First Received: | January 21, 2000 |
Last Updated: | July 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00000435 |
Health Authority: | United States: Food and Drug Administration |
RA Immune Modulation Oral Tolerance Peptide dnaJ |
Autoimmune Diseases Musculoskeletal Diseases Joint Diseases Arthritis |
Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases |
Immune System Diseases |